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The discovery of penicillin in 1928 and its subsequent intro-
duction into clinical practice in 1941, heralded a new era in the
treatment of serious bacterial infections, including those
caused by Staphylococcus aureus . This organism causes a
wide range of infections in humans, with bloodstream infec-
tion and endocarditis being the most serious and potentially
devastating. However, despite the discovery of antibiotics,
S. aureus continues to cause a significant burden of illness
around the world, with a high mortality rate for invasive
disease [1]. One of the reasons for this is the ability of the
organism to continually evolve and adapt to new environ-
ments, including antibiotic exposures, resulting in the ongoing
accumulation of antibiotic resistance [2]. Remarkably,
penicillin-resistant S. aureus was detected within 1 year of
the clinical use of penicillin, and the progressive acquisition of
antibiotic resistance in S. aureus since that time, particularly
methicillin-resistant S. aureus (MRSA), has severely impact-
ed the available antibiotic armamentarium. As an example of
how serious this problem is, over the past 10 years, there have
been more deaths from invasive MRSA infection than human
immunodeficiency virus infection in the USA [3], yet MRSA
comprises less than half of all S. aureus infections.
In day-to-day practice, clinicians rely on susceptibility re-
sults from the diagnostic microbiology laboratory to guide
appropriate antimicrobial therapy for their patients. Most sus-
ceptibility tests performed in these laboratories rely on in vitro
phenotypic methods, where the test organism is exposed to
different concentrations of antibiotic and the impact on growth
of the organism is determined. Performance and interpretation
guidelines for these assays are provided by regulatory author-
ities such as the Clinical and Laboratory Standards Institute,
and European Committee on Antimicrobial Susceptibility
Testing. The minimum inhibitory concentration (MIC) is the
lowest concentration of an antimicrobial that will completely
inhibit the growth of an organism after a defined period of
incubation, usually 18 to 24 h, and is used by diagnostic
microbiology laboratories to define antimicrobial susceptibility
or resistance. All clinicians are aware, andmedical students are
taught, not to use an antibiotic to treat a bacterial infection if the
report from the microbiology laboratory indicates it is resistant
to that antibiotic. There is, however, a limitation to the current
methods for antimicrobial susceptibility testing—they are per-
formed in vitro and therefore do not measure other potentially
important factors influencing the in vivo activity of the agent.
Aside from antibiotics, other significant contributors to the
clearance of bacterial infections are the innate immune system
factors including host defense peptides (HDPs) and neutro-
phils. Host defense peptides have received increasing atten-
tion in the scientific literature because of their antimicrobial
activity against a wide range of pathogens, including drug-
resistant bacterial strains [4]. These amphipathic cationic pep-
tides are naturally occurring antimicrobials produced by a
variety of cell types such as epithelial cells and phagocytes
[5], and while they have direct antimicrobial activity against
human pathogens and cancer cells in vitro, they are increas-
ingly recognized as important immunomodulators in vivo [6].
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The cationic nature of HDPs is important for their activity,
with the positive charge promoting attachment at anionic
surfaces such as teichoic acids in the cell wall of Gram-
positive bacteria [7]. Factors that alter cell surface charge,
therefore, have the capacity to alter HDP function. While the
direct antibacterial mechanism of action of HDPs is not
completely understood, they act via inserting into the cyto-
plasmic membrane and appear to exert activity by either
disrupting the physical integrity of the bilayer, or translocate
across the membrane and act on internal targets [7].
The threat posed by increasing and emerging antimicrobial
resistance in S. aureus is a significant public health problem.
S. aureus is one of the ESKAPE organisms, highlighted by
The Infectious Diseases Society of America in their “Bad
Bugs, No Drugs” policy report in 2004 and requiring the
development of novel antibacterial agents [8]. The lack of
new antimicrobials in the increasingly dry drug development
pipeline, and increasingly common and novel-resistance
mechanisms continue to provide challenges for clinicians.
For this reason, clinicians and scientists, while continuing to
hope for the arrival of new antibacterial agents, are now also
looking backwards to explore opportunities to use previously
discarded agents (for example, the re-introduction of colistin
for pan-resistant Gram-negative infections), or to use well-
established agents in a different way. In this issue of the
journal, Sakoulas et al. [9] have investigated the innate im-
mune system impacts of a relatively old class of antibiotics
(the β-lactams) against MRSA, and demonstrate that we still
have a lot to learn about how some antimicrobial agents exert
their full clinical effect. Their findings suggest that the stan-
dard antimicrobial susceptibility result that is delivered from
the diagnostic microbiology laboratory may not always tell
the whole truth.
In infectious diseases clinical practice combination antimi-
crobial therapy is often employed to treat life-threatening
bacterial infections including S. aureus bacteremia; however,
the clinical utility of this practice is not well established.
Recently, reports have emerged describing the use of β-
lactams that the infecting organism is resistant to, in combi-
nations with other antibacterials, to improve outcomes in
difficult-to-treat infections caused by S. aureus and Entero-
coccus faecium [10, 11]. The rationale behind this has been
that the β-lactam, despite the phenotypic resistance of the
organism, has resulted in changes to the bacterial surface
promoting enhanced binding and activity of the other antibi-
otic, daptomycin. The addition of ampicillin to cultures of an
ampicillin-resistant E. faecium strain-enhanced binding and
activity of daptomycin as well as host defense peptides tested
in vitro, possibly mediated by alterations in cell surface charge
[11]. Similarly, the addition of anti-staphylococcal penicillins
to the treatment of a small number of refractory MRSA
bacteremia cases appeared to result in the resolution of infec-
tion, and the addition of anti-staphylococcal penicillins to
MRSA cultures reduced surface charge, enhanced daptomy-
cin binding, and improved daptomycin activity [10]. In the
article by Sakoulas et al. [9], the potential mechanism
resulting in the clinical efficacy of β-lactams against the
resistant pathogen MRSA have been explored. The authors
have uncovered an intriguing phenomenon where low doses
of the antibacterial agent nafcillin enhanced killing of MRSA
(S. aureus resistant to all β-lactams including nafcillin)
through promoting the activity of HDPs and neutrophils.
Fig. 1 Tentative model illustrating the impact ofβ-lactam antibiotics on innate immunemediated killing of methicillin-resistant Staphylococcus aureus
(MRSA), based on the data from Sakoulas et al. [9]
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The authors found that low doses of nafcillin (e.g.,
20 μg/ml, when the MIC of the strains was >128 μg/ml)
increased the in vitro activity of the cationic antimicrobial
peptide LL-37 and other mammalian HDPs, and ex vivo
increased killing of MRSA by neutrophils, keratinocytes,
and human whole blood (Fig. 1). Other β-lactam antibiotics
demonstrated a similar in vitro effect although not all to the
same degree as nafcillin, while non-β-lactams had minimal
effect. A number of experiments supported the conclusion that
low-dose nafcillin was promoting antibacterial activity of
HDPs, with nafcillin promoting the enhanced binding of LL-
37 demonstrated on the surface of an MRSA strain. It may be
that the reduction in cell surface charge noted after β-lactam
exposure of MRSA in previous studies [10, 11] is responsible
for the enhanced binding and activity of HDPs; however, this
requires further clarification. Daptomycin, the antibiotic used
clinically in combination with the β-lactams to successfully
treat the reported cases is also positively charged in vivo after
binding divalent calcium, and in fact, has a mechanism of
action reminiscent of HDPs, suggesting that the β-lactam
could be promoting activity of innate HDPs and daptomycin
concurrently.
Recent studies have suggested that the in vivo activity of
HDPs may be linked more to immunomodulatory effects rather
than direct antibacterial activity [6]. The most compelling result
of the study by Sakoulas et al. [9], however, was the attenuation
of virulence of MRSA in the mouse skin infection model, upon
pre-exposure to nafcillin, or upon treatment of mice with
nafcillin alone, suggesting a direct impact on innate immune
mediated killing in this model. Importantly, therefore, these
results indicate that the nafcillin-mediated effects observed
in vitro and ex vivo may translate into important in vivo activ-
ity. Interestingly, a recent completed clinical study that assessed
the benefit of adding a β-lactam to traditional therapy
(vancomycin) for the treatment of MRSA bacteremia cases
has demonstrated an improvement in microbiological outcome
with the addition of the β-lactam [12]. This was a retrospective
study, and clearly large-scale prospective controlled clinical
studies are now needed to formally evaluate the clinical benefit
of adjunctive β-lactam therapy and the optimal combination
therapies for MRSA bacteremia. While the authors have un-
covered positive effects of nafcillin exposure against MRSA
strains tested in vitro and in a mouse skin infection model, it
remains possible that negative consequences of the use of such
combinations could occur with the treatment of infections in
humans, which will only be detected with appropriate prospec-
tive clinical studies. Human research ethics committees could
have some difficulty justifying the use of an antimicrobial that
the infecting strain has demonstrated in vitro resistance to.
Here, Sakoulas et al. have provided biological plausibility to
the role of adjuvant β-lactams in resistant MRSA bacteremia,
that further support the preliminary data from clinical case
series and retrospective studies.
There are still many unanswered questions from a mecha-
nistic point of view. In particular, the cellular changes promot-
ing nafcillin-enhanced innate immune killing have not been
defined. Clearly, transcriptomic and comparative proteomic
studies could provide some interesting insights here, and it
appears that the authors are planning these. Further insights
gleaned from these studies may provide novel avenues for
treatment of MRSA strains in future.
It is not uncommon in clinical infectious diseases practice
to encounter a patient with MRSA bacteremia that persists
despite apparent appropriate antibiotic therapy. So what will I
do in this situation in future if the patient is receiving vanco-
mycin or daptomycin and remains bacteraemic? I will be
increasingly inclined to add a β-lactam antibiotic to the reg-
imen, with increasing clinical experience demonstrating the
potential efficacy of this decision, and the study by Sakoulas
et al. providing insights into the potential basis for the clinical
efficacy of the additional agent. How then will I answer the
medical student when they ask why I am adding an agent to
which the infecting pathogen is resistant? I will tell them that
“there appears to be more to antibacterial therapy than meets
the eye (or MIC).”
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